Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity

BJU International

Volumn 102, Issue 11, 2008, Pages 1566-1572

  Barbero, Giovanna ^a   Destefanis, Paolo ^b   Procida, Simone ^a   Mandili, Giorgia ^a   Ulliers, Daniela ^a   Ceruti, Carlo ^b   Fiori, Cristian ^b   Maule, Milena M ^a   Fontana, Dario ^b   Giribaldi, Giuliana ^a   Turrini, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Dipartimento di Discipline Medico Chirurgiche   (Italy)

Author keywords

BPH; Circulating cells; Prostate cancer; Prostate specific antigen; Quantitative RT PCR

Indexed keywords

PRIMER DNA; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER CELL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXON; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

FEASIBILITY STUDIES; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 56649094481     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07797.x     Document Type: Article

References (23)

1. Shah JB, Reese AC, McKiernan JM, Benson MC. PSA updated: still relevant in the new millennium? Eur Urol 2005 47 : 427 32
2. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004 172 : 1297 301
3. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997 158 : 326 37
4. Schamhart DH, Maiazza R, Kurth KH. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review). Int J Oncol 2005 26 : 565 77
5. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 2006 18 : 48 56
6. Hara N, Kasahara T, Kawasaki T et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002 8 : 1794 9
7. Llanes L, Ferruelo A, Paez A, Gomez JM, Moreno A, Berenguer A. The clinical utility of the prostate specific membrane antigen reverse- transcription/polymerase chain reaction to detect circulating prostate cells: an analysis in healthy men and women. BJU Int 2002 89 : 882 5
8. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995 55 : 2640 4
9. Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA. Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. Eur Urol 2002 41 : 363 71
10. Ellis WJ, Vessella RL, Corey E et al. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 1998 159 : 1134 8
11. Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007 112 : 3000 9
12. Martinez-Pineiro L, Rios E, Martinez-Gomariz M et al. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur Urol 2003 43 : 342 50
13. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005 109 : 365 79
14. Patel K, Whelan PJ, Prescott S et al. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res 2004 10 : 7511 9
15. Zambon CF, Basso D, Prayer-Galetti T et al. Quantitative PSA mRNA determination in blood: a biochemical tool for scoring localized prostate cancer. Clin Biochem 2006 39 : 333 8
16. Llanes L, Ferruelo A, Lujan M, Pascual C, Garcia-Mediero JM, Berenguer A. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2005 8 : 248 52
17. Gelmini S, Tricarico C, Vona G et al. Real-Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the taqman detection system. Clin Chem Laboratory Med 2001 39 : 385 91
18. Straub B, Muller M, Krause H, Schrader M, Miller K. Quantitative real-time rt-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients. Oncology 2003 65 (Suppl. 1 12 7
19. Straub B, Muller M, Krause H et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using 'Light-Cycler'-based quantitative real-time polymerase chain reaction. Urology 2001 58 : 815 20
20. Giribaldi G, Procida S, Ulliers D et al. Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method. J Mol Diagn 2006 8 : 105 12
21. Mejean A, Vona G, Nalpas B et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 2000 163 : 2022 9
22. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007 450 : 1235 9
23. Cohen SJ, Alpaugh RK, Gross S et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006 6 : 125 32